1. Home
  2. CISO vs INAB Comparison

CISO vs INAB Comparison

Compare CISO & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CISO Global Inc.

CISO

CISO Global Inc.

HOLD

Current Price

$0.33

Market Cap

16.3M

Sector

Technology

ML Signal

HOLD

Logo IN8bio Inc.

INAB

IN8bio Inc.

HOLD

Current Price

$1.48

Market Cap

14.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CISO
INAB
Founded
2015
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
16.3M
14.2M
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
CISO
INAB
Price
$0.33
$1.48
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$6.00
AVG Volume (30 Days)
208.7K
69.1K
Earning Date
05-14-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
79.31
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.31
$0.12
52 Week High
$1.70
$4.20

Technical Indicators

Market Signals
Indicator
CISO
INAB
Relative Strength Index (RSI) 43.38 46.00
Support Level $0.32 $1.35
Resistance Level $0.38 $2.11
Average True Range (ATR) 0.03 0.09
MACD 0.00 0.02
Stochastic Oscillator 29.49 80.00

Price Performance

Historical Comparison
CISO
INAB

About CISO CISO Global Inc.

CISO Global Inc provides cybersecurity services. The services are used to protect client's data, financial information, intellectual property, and business reputation. The services include penetration testing, security remediation, compliance auditing, vulnerability assessment, and others. Geographically, the company operates in U.S., Chile and All other countries. The maximum revenue is generated from U.S.

About INAB IN8bio Inc.

IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.

Share on Social Networks: